ライフサイエンスコーパス: absorbable

1 ecovery and biofilm formation from explanted absorbable (AB) and nonabsorbable (NAB) sutures from inf

2 of the need to convert water-soluble, poorly absorbable, active site inhibitors into fat-soluble prod

3 c agents, subcategorized as physical agents, absorbable agents, biologic agents, and synthetic agents

4 othesis that the microbiota-generated TPP is absorbable and could contribute toward host thiamine hom

5 uture removal, as well as between RCTs using absorbable and non-absorbable sutures removed >/=10 days

6 nificant differences in CRC outcomes between absorbable and non-absorbable sutures when they were rem

7 were treated with a prolonged course of non-absorbable antibiotics via the drinking water, which res

8 a sodium hyaluronate/carboxymethylcellulose absorbable barrier developed to prevent adhesions after

9 Guided bone regeneration (GBR) using a non-absorbable barrier has provided clinicians the ability t

10 to be equal to, if not better than, the non-absorbable barrier.

11 bnitrate (BSN), which establishes a depot of absorbable Bi and produces morphological signs of neurot

12 Some plants provide absorbable calcium, but the quantity of vegetables requi

13 sulin secretion through avoidance of rapidly absorbable carbohydrates.

14 Hemostasis was achieved by placing absorbable cellulose fabric down the probe tract.

15 om intestinal micelles, reducing the pool of absorbable cholesterol, but they are also rapidly taken

16 A novel, absorbable-coating sirolimus-eluting stent (AC-SES) was

17 rforations were repaired during surgery with absorbable collagen membrane barriers.

18 ee defects were implanted with rhBMP-2 in an absorbable collagen sponge (ACS) carrier (positive contr

19 ues, the PRP preparation soak-loaded onto an absorbable collagen sponge (ACS) carrier or ACS alone wa

20 e bone regenerative ability of rhBMP-2 on an absorbable collagen sponge (ACS) carrier to a collagen s

21 or E. coli-derived rhBMP-2 (0.2 mg/mL) in an absorbable collagen sponge (ACS) carrier.

22 The use of rhBMP-2/absorbable collagen sponge (ACS) combined with all of th

23 rphogenetic protein-2 (rhBMP-2) loaded in an absorbable collagen sponge (ACS) in human extraction sit

24 owing surgical implantation of rhBMP-2 in an absorbable collagen sponge (ACS) or a calcium phosphate

25 L) in a tricalcium phosphate/hydroxyapatite/ absorbable collagen sponge composite (TCP/HA/ACS) or cal

26 In experimental hemimandibles, rhBMP-2/absorbable collagen sponge was well mixed with allograft

27 Although these membranes are absorbable, collagen membranes have been demonstrated to

28 nts undergoing GTR procedures with synthetic absorbable devices for the treatment of gingival recessi

29 Lactulose is a non-absorbable disaccharide, which alters the intestinal lum

30 ound insufficient evidence about whether non-absorbable disaccharides are beneficial.

31 Application of temporary, absorbable embolization materials could be advantageous

32 etary complex carbohydrates, liberating host-absorbable energy via fermentation products.

33 absorbable barrier (test treatment) or a non-absorbable ePTFE barrier (control treatment).

34 cedures with comparable success rates to non-absorbable expanded polytetrafluoroethylene (ePTFE) memb

35 rgarine-type spreads, containing 35% and 60% absorbable fat, was 6.5 and 6.4 g/100 g after production

36 After that, the non-absorbable fraction was anaerobically incubated with hum

37 crospheres, polyvinyl alcohol particles, and absorbable gelatin powder were injected into the hepatic

38 gauze control groups, while no sites in the absorbable gelatin sponge group had an adverse event.

39 as normal to rapid healing, compared to the absorbable gelatin sponge group where 40% of the sites w

40 control group patients were treated with an absorbable gelatin sponge.

41 ising: 1) oxidized regenerated cellulose; 2) absorbable gelatin sponge; or 3) sterile gauze with exte

42 ogically blocking protein ascorbylation with absorbable guanidino compounds is feasible and may repre

43 ula, bioprosthesis, biocompatible materials, absorbable implants, dermis, and collagen.

44 fficacy for 5 weeks after implantation of an absorbable inferior vena cava (IVC) filter in a swine mo

45 Conclusion An absorbable IVC filter can be safely deployed in swine an

46 Eleven absorbable IVC filters made from polydioxanone suture we

47 clinical trial of coronary implantations of absorbable magnesium stents.

48 to undergo periodontal therapy utilizing non-absorbable membranes agreed to have sterile polypropylen

49 anes have been shown to be comparable to non-absorbable membranes with regard to probing depth reduct

50 Use of absorbable membranes, root conditioning, shallow pretrea

51 eral edema resolved, bedside pleating of the absorbable mesh allowed delayed fascial closure in 37 pa

52 im of the study was to evaluate biosynthetic absorbable mesh in single-staged contaminated (Centers f

53 wall defects consists of 3 stages: stage I, absorbable mesh insertion for temporary closure (if edem

54 Absorbable mesh provides effective temporary abdominal w

55 allowing delayed fascial closure); stage II, absorbable mesh removal in patients without edema resolu

56 prospective longitudinal study, biosynthetic absorbable mesh showed efficacy in terms of long-term re

57 trial of 3 methods of repair: sutures versus absorbable mesh versus nonabsorbable mesh.

58 ed in 23.1% after suture repair, 30.8% after absorbable mesh, and 12.8% after nonabsorbable mesh (P =

59 tal of 126 patients enrolled: 43 sutures, 41 absorbable mesh, and 42 nonabsorbable mesh.

60 s; and inability to belch at 12 months after absorbable mesh.

61 temporary closure with polyglactin 910 woven absorbable mesh.

62 ce of a novel second-generation drug-eluting absorbable metal scaffold (DREAMS 2G) in patients with d

63 This serial analysis of drug-eluting absorbable metal scaffold confirmed the safety and effic

64 This novel absorbable metal scaffold could be an alternative to abs

65 The drug-eluting absorbable metal scaffold has demonstrated feasibility,

66 g the safety and performance of drug-eluting absorbable metal scaffold in 46 patients with coronary a

67 long-term vascular responses to drug-eluting absorbable metal scaffold.

68 vercome the limitations of conventional, non-absorbable metal-based drug-eluting stents.

69 echnique using inverting sutures with slowly absorbable monofilament material seems preferable.

70 ne laparotomy should be closed with a slowly absorbable monofilament suture material in a continuous

71 hus recommended to account for the amount of absorbable monosaccharides of foods for portion size cal

72 that breaks down di- and oligosaccharides to absorbable monosaccharides.

73 rocyanidins, particularly the polymers, into absorbable oligomers.

74 Determine whether absorbable or nonabsorbable mesh in repair of large hiat

75 KD and whether it was modifiable by altering absorbable phosphate.

76 rocessed and fast foods enriched with highly absorbable phosphorus additives.

77 that provided highest amounts of potentially absorbable phytoene/phytofluene was by far tomato juice

78 Absorbable plates and screws as well as cyanoacrylate gl

79 The coating consisted of absorbable poly-lactide-co-glycolic acid (PLGA) and crys

80 chnique of continuous suturing with a slowly absorbable (polydioxanone) suture material in a wound-su

81 chnique of continuous suturing with a slowly absorbable (polydioxanone) suture material reduces the r

82 ed lesions were veneered by a rapidly formed absorbable polymer barrier of poly(DL-lactide) to enhanc

83 MiStent is a drug-eluting stent with a fully absorbable polymer coating containing and embedding a mi

84 In our early clinical experience with the absorbable polymer matrix scaffold P4HB, it seemed to pr

85 analysis of our initial experience with the absorbable polymer scaffold P4HB compared with a consecu

86 To evaluate the use of the new absorbable polymer scaffold poly-4-hydroxybutyrate (P4HB

87 P4HB, an absorbable polymer scaffold, may present a new alternati

88 le metal scaffold could be an alternative to absorbable polymeric scaffolds for treatment of obstruct

89 So far, only polymeric absorbable scaffolds are commercially available.

90 Absorbable scaffolds were designed to overcome the limit

91 Biocompatible, rapidly absorbable stent coatings enable the matching of drug re

92 uit punches contain large amounts of readily absorbable sugars and may contribute to weight gain and

93 essive calories and large amounts of rapidly absorbable sugars.

94 However, the use of a longer-acting absorbable suture increases the rate of suture reaction

95 y of included RCTs (59%) reported use of non-absorbable suture materials.

96 Suturing is done with a 6-0 monofilament absorbable suture, but one can utilize any 5-0 or 6-0 su

97 ell as between RCTs using absorbable and non-absorbable sutures removed >/=10 days postoperatively.

98 s in CRC outcomes between absorbable and non-absorbable sutures when they were removed >/=10 days aft

99 ocyanidin dimers, trimers, and tetramers are absorbable, whereas larger oligomers are not.

100 e considered when their usual diet is low in absorbable zinc; severe stunting, low plasma zinc, or bo